Are you Dr. Farajallah?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 37 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
777 Scudders Mill Rd
Ms P11-26
Plainsboro, NJ 08536Phone+1 609-897-3124Fax+1 609-897-6068
Summary
- Dr. Awny Farajallah, MD is an infectious disease specialist in Plainsboro, New Jersey. He is currently licensed to practice medicine in New Jersey, Pennsylvania, and Arkansas.
Education & Training
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 1995 - 1998
Cairo University School of MedicineClass of 1991
Certifications & Licensure
NJ State Medical License 2002 - 2025
AR State Medical License 1997 - 2021
PA State Medical License 2004 - 2008
Awards, Honors, & Recognition
- Fellow (FACP) American College of Physicians, 2006
Publications & Presentations
PubMed
- 102 citationsSimplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiret...Edwin DeJesus, Benjamin Young, Javier O Morales-Ramirez, Louis Sloan, Douglas J. Ward
Journal of Acquired Immune Deficiency Syndromes. 2009-06-01 - 51 citationsEscherichia coli: Development of Carbapenem Resistance During TherapyTao Hong, Ellen Smith Moland, Baha Abdalhamid, Nancy D. Hanson, Jie Wang
Clinical Infectious Diseases. 2005-05-15 - 236 citationsAbacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.Paul E. Sax, Camlin Tierney, Ann C. Collier, Margaret A. Fischl, Katie R. Mollan
The New England Journal of Medicine. 2009-12-16
Press Mentions
Phase 3 Trial of ICLUSIG® (Ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the USNovember 17th, 2022- Chutes & Ladders—AstraZeneca Internally Promotes Galbraith to Helm Cancer R&DJuly 2nd, 2021
- BioSpace Movers & Shakers, July 2July 1st, 2021
- Join now to see all
Professional Memberships
- Fellow
